CIK 0001395937 · Large accelerated filer
Syndax Pharmaceuticals Inc
Sign in to watch- Ticker
- SNDX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 320162505
- Phone
- 781-419-1400
- Business address
- 730 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY, 10017
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $113,716
- in 1 filing, $114K under 10b5-1 plans
Net −$113,716. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 25 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-10-30 | Meyers Michael L. SVP, Chief Medical Officer | Purchase | +200 | $4.79 | $958 | 2,398 |
| 2018-09-25 | Jarrett Jennifer Director | Grant or award · Stock Option (Right to Buy) | +35,000 | 35,000 | ||
| 2018-09-25 | Meury William Director | Grant or award · Stock Option (Right to Buy) | +35,000 | 35,000 | ||
| 2018-06-18 | BVF PARTNERS L P/IL 10% owner | Other disposition | −1,105,391 | 498,025 | ||
| 2018-06-18 | BVF PARTNERS L P/IL 10% owner | Other disposition | −705,863 | 318,021 | ||
| 2018-06-18 | BVF PARTNERS L P/IL 10% owner | Other disposition | −188,746 | 85,038 | ||
| 2018-06-18 | BVF PARTNERS L P/IL 10% owner | Other acquisition · Warrants | +1,105,391 | 1,105,391 | ||
| 2018-06-18 | BVF PARTNERS L P/IL 10% owner | Other acquisition · Warrants | +705,863 | 705,863 | ||
| 2018-06-18 | BVF PARTNERS L P/IL 10% owner | Other acquisition · Warrants | +188,746 | 188,746 | ||
| 2018-05-23 | Chen Henry Director | Grant or award · Stock Option (Right to Buy) | +14,000 | 14,000 | ||
| 2018-05-23 | Egros Fabrice Director | Grant or award · Stock Option (Right to Buy) | +14,000 | 14,000 | ||
| 2018-05-23 | EVNIN LUKE Director | Grant or award · Stock Option (Right to Buy) | +14,000 | 14,000 | ||
| 2018-05-23 | Katkin Keith Director | Grant or award · Stock Option (Right to Buy) | +14,000 | 14,000 | ||
| 2018-05-23 | Legault Pierre Director | Grant or award · Stock Option (Right to Buy) | +14,000 | 14,000 | ||
| 2018-05-23 | Podlesak Dennis Director | Grant or award · Stock Option (Right to Buy) | +14,000 | 14,000 | ||
| 2018-04-03 | Ordentlich Peter Chief Scientific Officer | Option exercise | +7,500 | $3.08 | $23K | 7,500 |
| 2018-04-03 | Ordentlich Peter Chief Scientific Officer | Sale | −7,500 | $15.00 | $113K | 0 |
| 2018-04-03 | Ordentlich Peter Chief Scientific Officer | Option exercise · Employee Stock Option (right to buy) | −7,500 | 0 | ||
| 2018-03-01 | Shea Richard P Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +48,000 | 48,000 | ||
| 2018-03-01 | Ordentlich Peter Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 |
Page 24 of 25 · 500 trades